InflaRx (IFRX) Retained Earnings (2016 - 2026)
InflaRx's (IFRX) quarterly Retained Earnings came in at $58.0 million in Q1 2026, up 18.24% year-on-year from $49.0 million in Q1 2025, and up 2.52% quarter-over-quarter from $56.5 million in Q4 2025.
InflaRx (IFRX) Retained Earnings (2016 - 2026) Analysis & Trends
InflaRx has disclosed Retained Earnings across 11 years of filings, most recently posting $58.0 million for Q1 2026.
- Retained Earnings for Q1 2026 came in at $58.0 million, up 18.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.0 million (up 18.24% YoY), and the FY2025 annual result was $56.5 million, up 115.92% from the prior year.
- Retained Earnings came in at $58.0 million for Q1 2026 at InflaRx, up from $56.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $58.0 million in Q1 2026 to a low of -$355.0 million in Q4 2024.
- The 5-year median for Retained Earnings is $43.1 million (2023), against an average of $22.2 million.
- Across the five-year window, Retained Earnings sank 923.78% in 2024 and soared 115.92% in 2025, its largest moves.
- InflaRx's Retained Earnings stood at $37.4 million in 2022, then increased by 15.29% to $43.1 million in 2023, then tumbled by 923.78% to -$355.0 million in 2024, then jumped by 115.92% to $56.5 million in 2025, then gained by 2.52% to $58.0 million in 2026.
- The last three Retained Earnings figures came in at $58.0 million (Q1 2026), $56.5 million (Q4 2025), and $56.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -838.07 Mn |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | 57.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.95 Mn |
| Dec 31, 2025 | 56.53 Mn |
| Sep 30, 2025 | 56.47 Mn |
| Jun 30, 2025 | 54.00 Mn |
| Mar 31, 2025 | 49.01 Mn |
| Dec 31, 2024 | -354.98 Mn |
| Sep 30, 2024 | 48.08 Mn |
| Jun 30, 2024 | 46.44 Mn |
| Mar 31, 2024 | 45.53 Mn |
| Dec 31, 2023 | 43.09 Mn |
| Sep 30, 2023 | 43.10 Mn |
| Jun 30, 2023 | 42.33 Mn |
| Mar 31, 2023 | 40.62 Mn |
| Dec 31, 2022 | 37.38 Mn |
| Sep 30, 2022 | 36.47 Mn |
| Jun 30, 2022 | 37.62 Mn |
| Mar 31, 2022 | 37.17 Mn |
| Dec 31, 2021 | 35.00 Mn |
| Sep 30, 2021 | 35.48 Mn |
| Jun 30, 2021 | 34.86 Mn |